Диссертация (1139554), страница 52
Текст из файла (страница 52)
// Scandinavian Journalof Immunology. 2008; 67: 441-447.133. Chen Z., Chen L., Baker K. et al. CEACAM1 dampens antitumor immunity bydown-regulating NKG2D ligand expression on tumor cells. // J Exp Med. 2011;208(13): 2633-40.134. Cheng M., Chen Y., Xiao W., Sun R., Tian Z. NK cell-based immunotherapy formalignant diseases. // Cellular & Molecular Immunology. 2013; 10(3): 230-252.135. Cheson B.D. Radioimmunotherapy of non-Hodgkin lymphomas.
// Blood. 2003;101: 391-398.136. Chiesa M.D., Sivori S., Carlomagno S., Moretta L., Moretta A. Activating KIRs andNKG2C in viral infections: toward NK cell memory? // Front Immunol. 2015; 6: 573.137. Chin L., Garraway L.A., Fisher D.E. Malignant melanoma: genetics and therapeutics in the genomic era. // Genes Dev. 2006; 20: 2149-2182.138. Chodon T., Comin-Anduix B., Chmielowski B. et al. Adoptive transfer of MART-1T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients withmetastatic melanoma.
// Clinical Cancer Research. 2014; 20: 2457-2465.139. Clarke K., Lee F.T., Brechbiel M.W. et al. In vivo biodistribution of a humanizedanti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nudemice. // Cancer Res. 2000; 60: 4804-4811.140. Claus M., Meinke S., Bhat R., Watzl C. Regulation of NK cell activity by 2B4, NTBA and CRACC. // Frontiers in Bioscience. 2008; 13: 956-965.141. Clausen J., Vergeiner B., Enk M. et al.
Functional significance of the activation-associated receptor CD25 and CD69 on human NK-cells and NK-like T-cells. // Immunobioljgy. 2003; 207(2): 85-93.142. Colonna M., Borsellino G., Falco M. et al. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. //PNAS.
1993; 90(24): 12000-12004.143. Conlon K.C., Lugli E., Welles H.C., Rosenberg S.A. et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine productionduring first-in-human clinical trial of recombinant human interleukin-15 in patients272with cancer. // J Clin Oncol. 2015; 33(1): 74-82.144. Cooley S., Trachtenberg E., Bergemann T.L. et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantationfor acute myelogenous leukemia.
// Blood. 2009; 113: 726-732.145. Cooper M.A., Fehniger T.A., Caligiuri M.A. The biology of human natural killer-cellsubsets. // Trends in Immunology. 2001; 22(11): 633-640.146. Corthay A. Does the immune system naturally protect against cancer? // Front Immunology. 2014; 5:197.147. Cosman D., Fanger N., Borges L. et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. // Immunity.
1997; 7: 273-282.148. Cosman D., Mullberg J., Sutherland C.L. et al. ULBPs, novel MHC class I-relatedmolecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity throughthe NKG2D receptor. // Immunity. 2001; 14: 123-133.149. Couzin Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. // Science.2013; 342, 6165: 1432-1433.150.
Crane C.A., Austgen K., Haberthur K., et al. Immune evasion mediated by tumorderived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients. // PNAS. 2014; 111(35): 12823-12828.151. Crocker P.R., Paulson J.C., Varki A. Siglecs and their roles in the immune system. //Nature Reviews Immunology. 2007; 7(4): 255-266.152. Dahlberg C.I., Sarhan D., Chrobok M., Duru A.D., Alici E. Natural Killer Cell-BasedTherapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity.
// Frontiers in Immunology. 2015; 6: 605.153. Davies J., Stringaris K., Barrett A.J., Rezvani K. Opportunities and limitations of NKcells as adoptive therapy for malignant disease // Cytotherapy. 2014; 16(11): 145366.154. De Andrade L.F., Smyth M.J., Martinet L. DNAM-1 control of natural killer cellsfunctions through nectin and nectin-like proteins. // Imm Cell Biology. 2013; 17: 95.155. De Maria A., Bozzano F., Cantoni C., Moretta L.
Revisiting human natural killer cellsubset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers ofabundant IFN-gamma on activation. // PNAS. 2011; 108: 728-732.273156. De Potter C.R., Schelfhout A.M., De Smet F.H. et al. A monoclonal antibody directedagainst a human cell membrane antigen prevents cell substrate adhesion and tumorinvasion. // Am. J. Pathol.
1994; 144: 95-103.157. Demagalhaes-Silverman M., Donnenberg A., Lembersky B. et al. Posttransplantadoptive immunotherapy with activated natural killer cells in patients with metastaticbreast cancer. // J Immunother. 2000; 23: 154-160.158. Dennehy K.M., Klimosch S.N., Steinle A. Cutting edge: NKp80 uses an atypicalhemi-ITAM to trigger NK cytotoxicity.
// Immunology. 2011; 186(2): 657-661.159. Diefenbach A, Jamieson A.M., Liu S.D., Shastri N., Raulet D.H. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. // Nature Immunology. 2000; 1: 119-126.160. Diefenbach A., Jensen E.R., Jamieson A.M., Raulet D.H. Rae1 and H60 ligands ofthe NKG2D receptor stimulate tumour immunity. // Nature. 2001; 413: 165-71.161. Doubrovina E.S., Doubrovin M.M., Vider E.
et al. Evasion from NK Cell Immunityby MHC Class I Chain-Related Molecules Expressing Colon Adenocarcinoma. // Immunology. 2003; 171: 6891-6899.162. Duan X., Deng L., Chen X. et al. Clinical significance of the immunostimulatoryMHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. // Medical Oncology. 2011. 28: 466-474.163. Dudley M.E., Yang J.C., Sherry R. et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparativeregimens. // Clinical Oncology.
2008; 26(32): 5233-5239.164. Ebert T., Bander N.H., Finstad C.L. et al. Establishment and characterization of human renal cancer and normal kidney cell lines. // Cancer Research. 1990; 50: 55315536.165. Eidenschenk C., Jouanguy E., Alcais A. et al. Familial NK Cell Deficiency Associated with Impaired IL-2- and IL-15-Dependent Survival of Lymphocytes.
// Immunology. 2006; 177: 8835-8843.166. El-Gazzar A., Groh V., Spies T. Immunobiology and conflicting roles of the humanNKG2D lymphocyte receptor and its ligands in cancer. // Immunology. 2013; 191:1509-1515.274167. Engels C.C., Charehbili A., van de Velde C.J. et al. The prognostic and predictivevalue of Tregs and tumor immune subtypes in postmenopausal, hormone receptorpositive breast cancer patients treated with adjuvant endocrine therapy: a DutchTEAM study analysis.
// Breast Cancer Res. Treat. 2015. 149(3): 587-596.168. Escudier B., Farace F., Angevin E. et al. Immunotherapy with interleukin-2 (IL2) andlymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2. // Eur J Cancer.1994; 30A:1078–83.169. Evans J.H., Horowitz A., Mehrabi M. et al.
A distinct subset of human NK cells expressing HLA-DR expand in response to IL-2 and can aid immune responses to BCG.// European Journal of Immunology. 2011; 41: 1924-1933.170. Farag S.S., Caligiuri M.А. Human natural killer cell development and biology. //Blood reviews.
2006; 20: 123-137.171. Fauriat C., Long E.O., Ljunggren H.G., et al. Regulation of human NK-cell cytokineand chemokine production by target cell recognition. // Blood. 2010; 115: 2167-2176.172. Ferlazzo G., Tsang M.L., Moretta L. et al. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NKcells. // Experimental Medicine. 2002; 195(3): 343-511.173. Fernandez L., Portugal R., Valentin J. et al. In vitro natural killer cell immunotherapyfor medulloblastoma.
// Frontiers in Oncology. 2013. 3: 94.174. Fernandez-Morera J.L., Rodriguez-Rodero S., Lahoz C. et al. Soluble MHC class Ichain-related protein B serum levels correlate with disease activity in relapsing-remitting multiple sclerosis. // Human Immunology. 2008; 69: 235-240.175. Flaherty K.T., Hennig M., Lee S.J. et al. Surrogate endpoints for overall survival inmetastatic melanoma: a meta-analysis of randomised controlled trials.
// The Lancetoncology. 2014. 15(3): 297-304.176. Foley B., Cooley S., Verneris M.R. et al. NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. // Blood. 2011; 118: 2784-2792.177. Fong L., Brockstedt D., Benike C., Wu L., et al. Dendritic cells injected via differentroutes and induce immunity in cancer patients.
// J Immunol. 2001; 166: 4254-4259.275178. Forget M.A., Malu S., Liu H., Toth C. et al. Activation and propagation of tumorinfiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cellsfor adoptive immunotherapy of melanoma. // Immunotherapy. 2014; 9(37): 448-460.179.
Freud A.G., Becknell B., Roychowdhury S. et al. A human CD34(+) subset residesin lymph nodes and differentiates into CD56bright natural killer cells. // Immunity.2005; 22(3): 295-304.180. Freud A.G., Caligiuri M.A. Human natural killer cell development. // ImmunologicalReviews. 2006; 214: 56-72.181. Freud A.G., Yokohama A., Becknell B. et al. Evidence for discrete stages of humannatural killer cell differentiation in vivo. // Exp Med. 2006; 203(4): 1033-1043.182.
Gabrilovich D.I., Bronte V., Chen S.H. et al. The terminology issue for myeloid-derived suppressor cells. // Cancer Research. 2007; 67: 425.183. Garg A., Barnes P.F., Porgador A. et al. Vimentin expressed on Mycobacterium tuberculosis - infected human monocytes is involved in binding to the NKp46 receptor.// Immunology. 2008; 181: 8797.184. Gasser S., Raulet D. The DNA damage response, immunity and cancer. // Seminarsin Cancer Biology. 2006; 16: 344-347.185.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
